Jinan Falanxiu Biotechnology Co., Ltd – Trademark Portfolio

Entity Type: 16

Jinan Falanxiu Biotechnology Co., Ltd holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 1 trademark is registered. Notable registered marks include FRANSAU. The owner is based in Jinan City.

Room 435, Building 5, China Resources Land Plaza, No. 68 Gongye South Road, Lixia District

Jinan City 250000 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

FRANSAU
FRANSAU
Registered 2024

Trademark Classifications

Jinan Falanxiu Biotechnology Co., Ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Jinan Falanxiu Biotechnology Co., Ltd have?

Jinan Falanxiu Biotechnology Co., Ltd has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned.

What trademark classes does Jinan Falanxiu Biotechnology Co., Ltd file in?

Jinan Falanxiu Biotechnology Co., Ltd files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Jinan Falanxiu Biotechnology Co., Ltd's most well-known trademarks?

Jinan Falanxiu Biotechnology Co., Ltd's registered trademark portfolio includes well-known marks such as FRANSAU. These are among 1 currently registered trademark in the portfolio.

What is Jinan Falanxiu Biotechnology Co., Ltd's trademark registration success rate?

Jinan Falanxiu Biotechnology Co., Ltd has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.